Remdesivir bei Patienten mit schwerer COVID-19
Author:
Publisher
Springer Science and Business Media LLC
Subject
Internal Medicine
Link
https://link.springer.com/content/pdf/10.1007/s00108-020-00800-5.pdf
Reference2 articles.
1. Kabisch M, Ruckes C, Seibert-Grafe M, Blettner M (2011) Randomized controlled trials: part 17 of a series on evaluation of scientific publications. Dtsch Arztebl Int 108(39):663–668. https://doi.org/10.3238/arztebl.2011.0663
2. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J et al (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395:1054–1062
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Antivirale Therapie bei Patienten mit COVID-19;Die Innere Medizin;2022-07-04
2. Remdesivir shifts circadian rhythmicity to eveningness; similar to the most prevalent chronotype in ADHD;Journal of Neural Transmission;2021-07
3. Third force in the treatment of COVID-19: A systematic review and meta-analysis;Annals of Medicine and Surgery;2021-05
4. Remdesivir: A potential game-changer or just a myth? A systematic review and meta-analysis;Life Sciences;2021-01
5. Building a hemodiafiltration system from readily available components for continuous renal replacement therapy under disasters and pandemics: preparing for an acute kidney injury surge during COVID-19;Current Opinion in Nephrology & Hypertension;2021-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3